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Abstract
Hepatitis C Virus (HCV) causes chronic infection and represents a global health burden. To date, there is no licensed
vaccine for HCV. The high viral replication rate and the existence of several HCV genotypes and quasispecies
hamper the development of an effective universal vaccine. In this regard, the current HCV vaccine candidates show
genotype-specific protection or narrow cross reactivity against other genotypes. Importantly, HCV spontaneous
clearance occurs in 15–50 % of infected subjects, indicating that natural resistance to chronic infection exists. This
phenomenon was demonstrated among humans and chimpanzees and continues to motivate researchers
attempting to develop an effective HCV vaccine. However, what constitutes a protective immune response or
correlate of protection against HCV infection is still vague. Additionally, the mechanisms behind successful HCV
clearance suggest the coordination of several arms of the immune system, with cell-mediated immunity (CMI)
playing a crucial role in this process. By contrast, although neutralizing antibodies have been identified, they are
isolate-specific and poorly correlate with viral clearance. Antigen-specific CD4 T cells, instead, correlate with
transient decline in HCV viremia and long-lasting control of the infection. Unfortunately, HCV has been very
successful in evading host immune mechanisms, leading to complications such as liver fibrosis, cirrhosis and
hepatocellular carcinoma. Interestingly, CMI to HCV antigens were shown among exposed individuals without
viremia or seroconversion, suggesting the clearance of prior HCV infection(s). These individuals include family
members living with HCV-infected subjects, healthcare workers, IV drug users, and sexual contacts. The correlates of
protection could be closely monitored among these individuals. This review provides a summary of HCV-specific
immune responses in general and of CMI in particular in these cohorts. The importance of these CMI responses are
discussed.
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Background
Hepatitis C virus (HCV) infection is a global health burden.
Nearly 185 million subjects (~3 %) of the world’s popula-
tion are affected by this virus. Liver cirrhosis, progressing
liver disease, and hepatocellular carcinoma (HCC) are com-
mon complications of chronic HCV infection [1, 2]. Pri-
mary infections with HCV are usually asymptomatic [3],
and the majority of cases develop chronic infection.
Approximately 15–50 % of infected individuals undergo
spontaneous viral clearance [4]. Figure 1 shows the possible
outcomes of HCV infection. Viral and host factors such as
gender, coinfections, and genetics are known to affect the
likelihood of clearance or persistence [5]. Figure 2 shows a
summary of the factors contributing to the different out-
comes of HCV infection. For example, interleukin 28B
(IL28B, also known as interferon lambda 3) single nucleo-
tide polymorphisms (SNP) have been used as predictors of
viral clearance with and without therapy [6–8]. In this
regard, infected patients with the IL28B.rs12979860 CC “fa-
vorable” allele are more likely to spontaneously clear HCV
infection and respond more favorably to interferon (IFN)-α
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treatment [6–8]. Natural protective immunity against
HCV has also been proven in both humans [9, 10] and
chimpanzees [11]. Importantly, host-specific cell-mediated
immunity (CMI) plays an essential role in the control of
HCV infection [12–14].
New vaccine strategies may benefit from targeting the
generation of potent high-avidity CD8 T-cell responses
which can clear virus-infected cells at mucosal surfaces.
Such T-cell responses could potentially prevent mucosal
transmission and significantly restrict the development of
chronic HCV infection. Importantly, HCV-specific mem-
ory CD4 and CD8 T cells were shown to persist for ap-
proximately 20 years after viral clearance among humans
[15] and also up to 7 years among chimpanzees [13]. The
mechanisms behind this phenomenon and how memory
responses are maintained are not well understood. Know-
ledge of factors that affect the differentiation of long-lived
effector and central memory cells are important for the
development of an effective T-cell vaccine [16].
Our current knowledge of HCV spontaneous clearance
is incomplete. However, natural resistance to infection
exists and continues to provide optimism to researchers
attempting to develop effective HCV vaccines [17, 18].
The high viral production rate and the existence of
seven different HCV genotypes and quasi-species has
hampered the design of an effective universal vaccine.
Several other factors also contribute to the lack of an ef-
fective HCV vaccine until now. Figure 3 summarizes the
known factors that contribute to the difficulties of pro-
ducing an effective HCV vaccine including the shortage
of funds for vaccine studies, the modest interest of
pharmaceutical companies and lack of a small and con-
venient animal model. All these factors contribute to the
failure in the development of an effective universal vac-
cine against HCV. On the other hand, there are great
advances in the development of newly direct acting anti-
virals (DAAs) for the treatment of HCV infection with
high cure rates. However, due to their high cost, there is
Fig. 1 Outcome of HCV infection. Different outcomes of HCV infection and the different possibilities are shown
Fig. 2 Factors affecting HCV natural history. Host factors are shown in the upper part of the figure and viral factors are shown in the lower part
of the figure. Coinfections and comorbidities also contribute to the outcome of infection
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a limited access to these new drugs in many parts of the
world, reviewed elsewhere [19]. To this end, there is a
great need for an effective pan- genotypic HCV vaccine.
Although HCV neutralizing antibodies have been
identified, these antibodies are isolate-specific and do
not correlate well with viral clearance [20]. In the ab-
sence of antibodies to HCV (anti-HCV) or detectable
viremia, HCV-specific CMI may represent the sole host
biomarker of exposure to this virus and may offer a pro-
tective mechanism against chronic HCV infection [10].
In this regard, what constitutes a protective immune re-
sponse or correlate of protection against HCV infection
is still vague. HCV-specific CMI was shown in exposed
uninfected subjects [21–29] without viremia or serocon-
version. This was documented among subjects such as
family members living with two or more HCV infected
subjects [24], sexual partners of acute HCV subjects
[27], intravenous drug users (IVDU) [25, 26] and health-
care workers (HCW) [28, 29]. Interestingly, HCV trans-
mission from seronegative blood donors was suggested
to occur via cellular blood products [30]. The above data
suggest that host immune responses likely determine the
course of HCV infection. It may be possible to define
the protective nature of HCV-specific CMI responses
among these individuals, and whether these responses
can be replicated by a vaccine.
Review
Innate immune responses to HCV infection
Similar to many viral infections, natural and adaptive
immune responses are essential in controlling HCV in-
fection. Hepatic innate immune reactions are linked to
natural killer (NK) cells, NKT cells, dendritic cells, Kupffer
cells and a quick IFN response mediated by infected hepa-
tocytes. NK and NKT cells lyse infected cells by releasing
granzymes and perforin. Additionally, these cells produce
huge amounts of type-II IFN (represented by IFN-γ) and
tumor necrosis factor alpha (TNF-α). HCV replication
cycle leads to the assembly of double stranded RNA
(dsRNA) intermediates that can trigger the expression of
type-I IFN genes. In this regard, the host cells identify
dsRNA through the pattern recognition receptors know as
Toll-like receptor 3 (TLR-3) [31]. Recognition of dsRNA
by TLR-3 leads to the activation of interferon regulatory
factor 3 (IRF-3). IRF-3 induces the expression of IFN-β
and interferon-stimulated genes (ISGs). IFNs act against
HCV replication in host cells and protect the uninfected
adjacent cells from infection with HCV by inducing the
expression ISGs. In this regard, the role of TLR-3 in viral
infections has been shown in knock-out mice that were
unable to mount a response to measles virus infection
[32]. Also, TLR-3 has been shown to mediate innate im-
mune responses against HCV infection [33].
Early defense against viral infection requires the stimu-
lation of type-I IFN, IFN-α and IFN-β. Mice that lack
IFN-α and IFN-β fail in resolving HCV infection [34].
Additionally, genetic defects in Signal Transducers and
Activators of Transcription-1 (STAT-1), which is in-
volved in the IFN signaling cascade, also result in death
of humans from viral disease(s) at an early age [35].
Among chimpanzees with acute HCV infection,
type-I IFN induced the expression of dsRNA-
dependent protein kinase R (PKR), 2’-5’ oligoadeny-
late synthetase (OAS) and Mx genes. These factors
Fig. 3 Causes of HCV vaccine failures
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have an essential part in inhibiting HCV replication
and inducing apoptosis of infected hepatocytes [36].
NK cells were, also, shown to have an essential part
in eliminating HCV without measurable T cell re-
sponses in chimpanzees [37].
Cellular immune response to HCV infection
Following acute infection with HCV, 15–50 % of infected
people will spontaneously clear their infection [38]. Sev-
eral studies suggest that successful viral clearance de-
pends on the coordination of multiple arms of the
immune system. Natural and specific immune responses
play an essential part in this process, which has been
reviewed elsewhere [39]. Vigorous and broad adaptive
immune responses have been identified in acutely in-
fected individuals and these responses endure among
those who clear the virus. By contrast, persistent infec-
tion correlates with weak, often unnoticeable T-cell re-
sponses [40].
The adaptive immune response includes two major
types of effector mechanisms: cellular responses com-
prising CD4 T helper (Th) cells and cytotoxic CD8 T
lymphocytes (CTL); and humoral responses consisting
of antibodies produced by HCV-specific B cells. Recog-
nition of a specific viral epitope/protein is required for
both adaptive immune effector mechanisms, which can
target any HCV protein. However, only some B cell epi-
topes localized on the viral envelope or capsid proteins
can induce HCV neutralizing antibodies and efficiently
prevent the binding and entry of the virus, i.e., prevent
HCV infection. Activated dendritic cells can present
HCV antigens to specific Th cells that respond by prolif-
eration and production of cytokines such as interleukin
(IL)-2, IFN-γ or IL-4. Th cell activation and cytokine
production is required for the development of CTL.
Ideally, stimulated CTL found in the liver will lyse HCV-
infected liver cells by cytolytic and non-cytolytic mecha-
nisms [41].
Th and CTL are essential for the control of HCV in-
fection in vivo. In this regard, the presence of strong T
cell responses to the virus is a common characteristic
among patients who clear their acute HCV infection.
However, strong CD4 and CD8 responses may also
occur in those who go on to chronic HCV infection. T
cell responses are usually weak among HCV chronic car-
riers. The part played by the HCV-specific T cell re-
sponse in controlling HCV infection is reinforced by
several observations. First, the appearance of HCV-
specific T cells in primary infection coincides with the
decline in HCV viral load. Additionally, intrahepatic
virus-specific CTL responses correlate with HCV clear-
ance and with hepatic inflammatory response [42]. Sec-
ond, a strong association between certain Class I and
Class II alleles of human leukocytic antigen (HLA) and
clearance of HCV infection has been reported. In this
regard, HLA Class-I A3 and B27 alleles were shown to
associate with protection and HCV clearance mediated
by a response to dominant CD8 T cell epitopes [43].
Third, studies in chimpanzees demonstrated that T cell
responses were essential for the HCV clearance/persist-
ence process [12, 13].
Although HCV-specific T-cells can be more numerous
in the peripheral blood mononuclear cells (PBMCs) of
chronic patients than in recovered subjects, the T-cells
in chronic subjects display a reduced proliferative re-
sponse. T-cell lines derived from chronic HCV patients
also displayed lower HCV-specific cytotoxicity when
compared with cell lines derived from recovered sub-
jects. Ex vivo IFN-γ production and the proliferation of
HCV-specific cells were also defective among chronic
patients. This defect could not be reversed by in vitro
stimulation with IL-2 and HCV peptides. Additionally,
the impairment of cytokine synthesis, cytotoxic function
and HCV-specific T cell proliferation among viremic pa-
tients was associated with weak in vitro Th responses
[44]. The highest frequency of HCV-specific response
measured by IFN-γ Enzyme-linked immunospot (ELI-
SPOT) assay were found within the first 8 weeks follow-
ing diagnosis of HCV infection [44]. Moreover, subjects
who spontaneously cleared their acute infection had a
greater and broader HCV-specific T cell response when
compared to their counterparts who developed chronic
infection. Importantly, subjects with chronic HCV infec-
tion failed to sustain these responses and their CMI re-
sponses dropped to undetectable levels only 1 year after
diagnosis of acute infection. By contrast, subjects who
spontaneously resolved their infection had detectable
HCV-specific T cell responses, although reduced in mag-
nitude, up to 12 months after diagnosis of acute infec-
tion. Antigen-specific IFN-γ production by CD8 T cells
declined more quickly during acute HCV-infection
among subjects who went on to chronic course of the
disease compared with their spontaneous resolution
counterparts. Also, the extent and breadth of CD8 T cell
responses acted similarly [45].
There is a need for comparative studies of the HCV-
specific memory T cells responses induced by natural in-
fection and by treatment. The part played by the immune
system in controlling the outcome of HCV therapy is de-
batable with reports showing an enhanced [46, 47], un-
affected or declining [48, 49] immune response among
individuals responding to IFN-based therapy. In this re-
gard, treatment of HCV infection at early stages could res-
cue long-lived HCV-specific memory T cells [50–52].
Importantly, IFN-α therapy has been shown to rescue
polyfunctional HCV-specific CTL; which persisted for up
to one year after therapy discontinuation [52]. On the
other hand, there are limited data examining the dynamics
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of HCV-specific CMI responses after treatment with the
new DAAs. In this regard, HCV-specific CTL were of nar-
row specificity among chronic HCV-infected chimpanzees
and were stable over time after successful treatment with
two DAAs [53].
Role of CD4 T cells
CD4 T cells deliver essential “help” for innate, cellular
and humoral immunity. T helper cells activate antigen
presenting cells, provide costimulatory signals for B
cells, and prime and sustain CTL responses. HCV-
specific Th cells correlate with transient and long-lived
viral control [54–56]. Viral clearance and liver inflam-
mation is usually synchronous with the buildup of HCV-
specific Th and CTL within 8–14 weeks following infec-
tion. Several reports have revealed the presence of
strong Th responses in spontaneously resolving HCV in-
fections [42, 57, 58]. In contrast to the poor and narrow
responses shown in those with chronic HCV, a strong,
broad, and Th1-biased Th response was found in sub-
jects with self-limited infection [59]. PBMCs isolated
from subjects with self-limited HCV infection showed a
Th1 cytokine profile, while those from chronic subjects
displayed a Th2 profile. This suggests that Th1 and not
Th2 responses are associated with a successful control
of the virus in the early phase of infection [60–63].
Additionally, serum levels of Th2 cytokines are increased
in chronic HCV infection and decrease during IFN-α
therapy [64]. The extent and specificity of Th responses
also seem to be essential for the control of HCV infec-
tion. In this regard, vigorous and multi-specific T cell re-
sponses and a sustained proliferation ability in response
to HCV antigens are dependable measures of a protect-
ive CMI during acute infection [44]. T cells from sub-
jects with spontaneously resolving HCV infection
recognized a mean of 10 out of 37 identified HCV epi-
topes. On the other hand, those from patients with HCV
persistence recognized only one epitope at max [65].
Circulating HCV-specific CD4 T cells from spontaneous
clearance subjects simultaneously targeted 4-14 epitopes
in the structural and non-structural HCV proteins for
up to several years after RNA disappearance from the
serum [65]. In summary, the above reports show that
strong, broad, and Th1- biased responses were identified
in spontaneous clearance subjects while poor and nar-
row responses were found among those who developed
chronic infection [59, 66].
Role of CD8 T cells
The effector functions of CTL include two overlapping
mechanisms: the killing of target cells and the non-cytolytic
production of antiviral cytokines. An IFN-γ-mediated non-
cytolytic pathway facilitates viral elimination, with >95 % of
HCV replication inhibition happening at a low effector to
target ratio [67]. Reports from animal studies, also, showed
that CTL migrate to the liver and contribute to controlling
HCV infection. The buildup of virus-specific CTL in the
liver synchronizes with increased liver enzyme levels and
with a transient decline in serum HCV-RNA levels [54, 68].
Like Th responses, the major player of spontaneously re-
solved HCV infection is a broad and multi-specific CTL re-
sponse [42, 69–71]. Contrasting this observation, CTL
responses are weak or target fewer epitopes in subjects hav-
ing chronic infections [42, 66, 72].
Role of T regulatory cells in HCV infection
Regulatory T (Treg) cells are a subpopulation of T-cells
that play an essential role in sustaining immune homeo-
stasis and the balance between tissue damage and immune
protection. Treg cells were proposed as a possible mechan-
ism for controlling HCV-specific responses [73–75].
Chronic HCV cases have an increased frequency of Treg
cells compared to controls and the Treg cells negatively
correlated with the degree of inflammation [76–78]. The
higher frequency of Treg cells may also explain the weak
HCV-specific T-cell responses in chronic HCV patients
[79]. There is also some evidence that chronic HCV
patients may harbour more Treg cells in their peripheral
circulation [80] and in the liver than those who are unin-
fected [81]. Thus, Treg cells appear to assist in the main-
tenance of chronic infection by inhibiting anti-HCV
responses and, therefore, attenuating the intrahepatic
tissue-damaging response to infection [79, 82].
CMI responses without viremia or seroconversion in high
risk subjects
1. Health care workers (HCW)
HCW are at an increased risk of HCV infection during
their work [83, 84]. The risk of getting HCV infection
from a contaminated needle is estimated at 0–5 %, or
approximately 10-times higher than the risk of HIV in-
fection via a comparable event [85, 86]. In general, the
occupational risk of acquiring HCV infection by a sur-
geon is below 0.03 %/year. This is true even when the
surgeon serves subjects with a high prevalence of HCV
infection [87]. The probability of HCV infection is likely
dependent on several features including viral load, time
and mode of injury. However, there is no scoring system
for the assessment of the risk of HCV infection after oc-
cupational exposure [28].
The detection of both anti-HCV antibodies and/or
HCV-RNA are usually used for the clinical determin-
ation of HCV infection. Anti-HCV seropositivity in the
absence of HCV-RNA indicates past HCV infection.
Importantly, HCV-specific T cell responses were docu-
mented among individuals with self-limited HCV
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infection [42, 58, 65]. Additionally, HCV-specific T cell
responses were reported among seronegative, aviremic
subjects [21, 24, 25, 88, 89]. These studies detected
HCV-specific T cells that reacted with different HCV
proteins by the secretion of cytokines such as IFN-γ.
Transient viremia without HCV-antibody seroconver-
sion was proposed as an explanation for the low inci-
dence of new HCV infections among HCW [90] and the
clearance of infection among other populations sup-
posedly exposed to low levels of HCV [23, 24, 26–28,
88, 91–93]. More than 50 % of 52 seronegative, aviremic
HCW had strong HCV multi-specific CMI responses
suggesting clearance of low level HCV infections. These
HCW were at a high risk of HCV infection by providing
healthcare to a high HCV prevalence patient cohort
[29]. These responses could arise from transient infec-
tion(s) with low titers of HCV-RNA that did not induce
the production of anti-HCV, as reported among humans
[22, 93, 94] and chimpanzees [37, 95]. The above data
suggest that relying only on the detection of HCV anti-
bodies to identify past exposure to the virus can lead to
a substantial underestimation of prior exposure to the
virus especially in endemic countries or among high-risk
populations. Unfortunately, the protective nature of
these responses and whether they protect these HCW
are difficult to prove in humans. This difficulty can be
ascribed to safety and ethical issues regarding the chal-
lenge of humans with live viruses.
Interestingly, a recent trial in four monkeys suggested
that exposures to sub-infectious doses of HCV actually
suppresses T cell responses upon subsequent acute in-
fection [96]. On the other hand, brief low viremia had
been documented in one HCW. This HCW remained
seronegative and aviremic for more than a year of
follow-up after transient viremia [90]. A similar observa-
tion was also documented among other HCW in Egypt
[97, 98]. These data suggest the exposure to and clear-
ance of HCV infection without antibody seroconversion.
These seronegative, aviremic HCW are frequently ex-
posed to HCV through occupational exposure. The CMI
responses found among these HCW may protect them
from HCV infection. An analogous phenomenon was
documented in IVDU who cleared primary HCV infec-
tions and were protected against consequent exposure
to HCV. This protection was largely due to T cell re-
sponses [10]. The above data demonstrate HCV-specific
T-cell responses in exposed seronegative, aviremic indi-
viduals [21–27, 99] including HCW in Europe [28, 89]
and Egypt [29, 100] and seem to be in a clear contrast to
the trial performed in monkeys [96]. If these CMI re-
sponses protect these individuals, they will certainly im-
pact the plans for HCV vaccine development, the
determination of past-exposure to the virus and disease
burden in different communities.
Evidence of HCV-specific T-cells producing IFN-γ was
shown among HCWs caring for chronic HCV patients
without any documented needle stick incidents [89].
HCV-specific T-cell secretion of IFN-γ was determined
for pooled HCV peptides from the core region in 10
healthy aviremic HCWs with ≥7 years of healthcare ex-
perience, and 30 HCV chronic subjects. Patients with
chronic HCV infection had a lower frequency of IFN-γ
spot forming cells (SFCs) than the HCW. Physicians and
nurses could have some exposure to HCV antigens that in-
duce IFN-γ production by T-cells regardless of the prophy-
lactic precautions undertaken while caring for chronic
HCV patients. This could be related to continuous expos-
ure of the immune system to HCV antigens. The exact
route of exposure to/transmission of HCV infection in
these individuals that leads to activation of T cells is mys-
terious and remains a subject of dispute [21, 27]. These
routes may include constant exposure to the virus as previ-
ously suggested [21], perhaps via skin micro-lesions or an
unprotected mucosa [101, 102], which happens during daily
patient care. Although these HCW had regular laboratory
monitoring, unreported or under estimated needle stick in-
juries cannot be excluded as a source of occupational ex-
posure to HCV [103]. Other routes of transmission are
likely present among immunocompromised and im-
munocompetent subjects. This was shown in hospital-
ized cancer patients without a known infection risk
who were diagnosed positive for HCV antibodies and
RNA [101, 104, 105].
2. Household contacts
Several studies reported HCV-specific CMI without
viremia or seroconversion among household contacts. In
one study, CMI was examined in persons exposed to
HCV without evidence of HCV infection. These persons
were living in a rural community in Egypt; where anti-
HCV prevalence was 24 %. Thirteen of 71 (18 %) sero-
negative subjects with a high-risk exposure to HCV (liv-
ing with ≥2 HCV-infected patients) and only one of 35
(2.9 %) seronegative low-risk subjects (no HCV-infected
subjects living in the household) had detectable CMI
[24]. The authors speculated that the subjects who were
seronegative and showed CMI-positive responses had a
transient very mild infection, probably due to exposure
to low-dose(s) of the virus which was subsequently
cleared. The presence of a prior HCV infection is
supported by the fact that the majority of the detected
responses were to non-structural HCV proteins; which is
an indication of HCV replication within these subjects.
Additionally, a substantial proportion of HCV-seronegative
aviremic Egyptian children at risk of infection developed
broad HCV-specific CMI. These responses were suggested
as a possible protective mechanism in these children
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against the development of chronic infection [88]. More-
over, strong HCV-specific CMI responses were demon-
strated among seronegative, aviremic children born to
mothers infected with HCV 3–8 years after birth [99]. The
children with transient viremia after birth had the strongest
IFN-γ responses to HCV antigens, particularly the NS3/
NS4 antigens, with up to 80 % responding to more than
one HCV antigen. In another study, CTL responses against
both the structural and non-structural HCV epitopes were
detected in 24.1 % of healthy family members who were
constantly exposed to chronic HCV persons (18). A similar
phenomenon was reported among sex-workers repeatedly
exposed to human immunodeficiency virus (HIV), without
detectable viremia or antibodies. These sex workers devel-
oped strong HIV-specific CMI responses against HIV-1 an-
tigens [106]. HIV-specific CMI was suggested as a
protective mechanism in these subjects against HIV-
infection, potentially leading to a quick control of the virus
prior to the development of antibody responses. Similarly,
some household contacts of HCV-infected patients or
IVDU with high risk exposures to HCV were shown not to
develop apparent infection despite repeated exposure to
HCV [107].
3. Sexual contacts and spouses
HCV-specific CMI responses in seronegative sexual
partners of chronic HCV patients was examined [92]. A
positive HCV-specific CMI response was documented
in the PBMCs of four subjects with occult HCV in-
fection without the detection of HCV antibodies. The
authors suggested that these CMI responses are bio-
markers for prior exposure and recovery from HCV,
and ongoing occult infection [92]. Sexual contacts of
acute HCV patients were tested with a set of 18
Class-I-restricted peptide antigens and recombinant
genotype 1 proteins [27]. A substantial number of ex-
posed subjects who remained persistently aviremic
and antibody negative developed both Th- and CTL-
restricted responses which were similar in breadth
and strength to that of subjects with primary and
self-limited HCV infections.
HCV-specific CMI against the core and NS3 proteins
of HCV genotype 1 were characterized in 32 seronega-
tive, aviremic individuals without risk of exposure to
HCV, 33 exposed seronegative, aviremic individuals and
20 uninfected individuals living with chronic HCV pa-
tients [108]. Twenty percent of apparently uninfected
subjects had measurable HCV-specific CMI. This fre-
quency is higher than prior estimates of HCV prevalence
in developed countries. These data are consistent with
spontaneously cleared primary HCV infections or infec-
tion that remained undetectable by traditional testing
methods.
4. IVDU and prisoners
High-risk prisoners showed HCV-specific immune re-
sponse without seroconversion and may have a higher
probability of HCV clearance [22]. The majority of 40
high risk seronegative, aviremic long-term IVDU had
HCV-specific CMI responses [109]. Fifty eight percent
of exposed uninfected IVDU produced IFN-γ in re-
sponse to HCV antigens compared with only 19 % of 21
control subjects. These responses were broad and tar-
geted several HCV proteins, eliminating cross-reactivity
to other antigens as a reason for these responses. These
responses may denote an imprint for HCV exposure
without viremia or antibody seroconversion. The same
group later demonstrated weak IFN-γ responses to both
structural and non-structural HCV antigens that were
significantly higher among exposed uninfected IVDU
compared to healthy controls. Among exposed seronega-
tive, aviremic cases, individuals who were not in rehabili-
tation demonstrated a significantly higher frequency of
IFN-γ producing cells in response to HCV antigens
when compared with those who stopped injections
[110]. Ongoing injecting behavior in the community or
in prison was suggested as a primer for these T-cell re-
sponses. Moreover, upon longitudinal follow-up, exposed
uninfected subjects continuing to inject drugs were
more likely to maintain a detectable IFN-γ response
when compared with those who stopped injections. It
was suggested that continued drug injection is crucial
for maintaining HCV-specific CMI, and that these re-
sponses are lost within months of stopping injections
[110]. Similar reports documented broad HCV-specific
T-cell responses among high-risk, seronegative aviremic
IVDU [23, 25, 26].
5. Hemodialysis patients
The HCV-specific T-cell functional profile was exam-
ined among high-risk seronegative, aviremic hemodialysis
patients [111]. Of seventy seven hemodialysis seronega-
tive, aviremic patients, 11.3 % displayed HCV-specific
CMI responses. Occult HCV infection was not a cause of
this CMI response as proven by nested RT-PCR. Interest-
ingly, based on the cytokine profile, two unique memory
T cell populations were found in these patients. These in-
cluded a polyfunctional population and another popula-
tion with a dominant TNFα production [111].
Theories behind the existence of CMI responses without
viremia or seroconversion
There are multiple possibilities for the development of T
cell responses in seronegative, aviremic subjects. These
include occult HCV infection with little viral replication
[112, 113], cross-reactivity to heterologous epitopes
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[114, 115], brief viral replication that does not lead to
antibody seroconversion [22, 95] and the loss of anti-
HCV antibodies following clearance of the virus [15].
However, it is not clear why only HCV-specific T cells,
but not B cells, are primed in seronegative, aviremic
individuals.
The existence of antigen-specific cellular responses in
some seronegative subjects may be explained by the
presence of cross-reactive T-cells responding to antigens
from unrelated organisms. In this regard, cross-reactive
Th cells against epitopes of diverse herpes viruses was
reported among humans [116]. Additionally, another
study reported the presence of cross-reactive CTL re-
sponses between influenza A and HCV [115]. The exist-
ence of a few HCV-peptide specific T cells among
humans does not necessarily indicate previous exposure
to HCV. Also, cross-reactivity with other infectious
agents can certainly affect the overall profile of HCV-
specific T cells [117]. In this regard, the viremia level
and HCV-specific immune responses were examined fol-
lowing viral inoculation of chimpanzees [95]. Infective
HCV doses of 1–10 RNA (+) virions induced detectable
CMI responses without viremia or seroconversion [95].
Another study also suggested that pre-existing CMI re-
sponses led to a more rapid expansion of adaptive im-
mune responses upon subsequent exposure to infectious
doses of HCV and a reduced frequency of chronic hepa-
titis [118]. Importantly, cross reactivity alone can not ex-
plain the HCV-multi-specific responses reported among
many HCW [29].
Summary
HCV spontaneous clearance remains poorly understood.
However, natural protective immunity against the virus
was documented in humans and chimpanzees. Host-
specific CMI responses seem to have an essential role in
this process. The high viral replication rate and the exist-
ence of seven HCV genotypes and quasispecies hamper
the development of a universally effective vaccine. Sev-
eral other factors also contribute to the unavailability of
an effective HCV vaccine. Although neutralizing anti-
bodies have been identified, they are isolate-specific and
poorly correlate with viral clearance. By contrast,
antigen-specific Th cells correlated with transient HCV
viremia and long-lasting viral control. Vigorous, broad,
and Th1-biased responses were identified among those
individuals that resolve HCV infection, contrasting with
the weak and narrow responses found among chronic
subjects.
In the absence of anti-HCV antibodies or detectable
viremia, CMI may represent the sole marker of host
contact with HCV and may offer a protective mechan-
ism against chronic hepatitis caused by this virus. HCV-
specific CMI was documented among exposed subjects
without viremia or seroconversion in several populations
e.g., HCW, family contacts, prisoners, sexual partners,
and IVDU. These data suggest the exposure to and
clearance of HCV infection without seroconversion.
Although direct challenge experiments cannot be per-
formed in humans, it is possible that long-lasting sero-
negative persistence in fertile discordant couples will be
able to prove, in the near future, the multiple exposure
and the immune-protection of the seronegative partners
as well as the part played by the immune response in
protection from HCV infection. Further support will be
provided by the seronegative, aviremic HCW constantly
exposed to HCV antigens. The CMI responses mounted
in these subjects can play a crucial role in their protec-
tion from HCV infection. An equivalent phenomenon is
present among IVDUs who spontaneously resolve a pri-
mary HCV infection and are resistant to secondary HCV
exposures. This protection correlates well with CMI
responses.
Identification of host protective immune responses
in subjects who spontaneously clear their HCV infec-
tion, and the longevity, magnitude, and breadth of the
response; particularly in seronegative, aviremic sub-
jects; is essential for the detection of prior exposure
to HCV, understanding its natural history, and under-
taking measures for its prevention. If these responses
are protective, then similar CMI responses need to be
simulated by future HCV vaccines. Unfortunately, the
protective nature of these responses and whether
those HCV-specific T cells in these seronegative,
aviremic groups were able to induce viral clearance
are difficult to prove in humans. Correlates of protec-
tion could be closely monitored among these sero-
negative, aviremic cohorts.
Conclusions
To date, there is no licensed HCV vaccine. The mecha-
nisms behind successful HCV clearance suggest the co-
ordination of multiple arms of the immune system, with
CMI playing an essential role in this process. HCV-
specific CMI has been reported among several high risk
subjects without viremia or seroconversion suggesting
clearance of prior infection(s) with HCV. Further studies
are needed to examine the longevity of HCV-specific
CMI responses in seronegative, aviremic subjects; par-
ticularly HCW; and to determine the dominant epitopes
in the responding antigens. It may be possible to define
the protective nature of HCV-specific CMI responses in
humans, and whether these responses can be replicated
by a vaccine.
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